Burden of breast cancer with brain metastasis: a French national hospital database analysis

References

• Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72
   PubMed Web of Science ®Google Scholar
• Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol 2005;4:289-98
   PubMed Web of Science ®Google Scholar
• Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-44
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Drappatz J, Wen PY. Chemotherapy and targeted molecular therapies for brain metastases. Expert Rev Neurother 2006;6:1465-79
   PubMedGoogle Scholar
• Patchell RA. The management of brain metastases. Cancer Treat Rev 2003;29:533-40
   PubMed Web of Science ®Google Scholar
• Ono M, Ando M, Yunokawa M, et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 2009;14:48-52
   Google Scholar
• Rades D, Lohynska R, Veninga T, et al. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer 2007;110:2587-92
   PubMedGoogle Scholar
• Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie 2002;25:474-9
   PubMed Web of Science ®Google Scholar
• Patel RR, Mehta MP. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 2007;13:1675-83
   PubMed Web of Science ®Google Scholar
• Peak S, Abrey LE. Chemotherapy and the treatment of brain metastases. Hematol Oncol Clin North Am 2006;20:1287-95
   Google Scholar
• Tomasello G, Bedard PL, de AE, et al. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol 2009;75:110-21
   Google Scholar
• Tosoni A, Franceschi E, Brandes AA. Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol 2008;68:212-21
   Google Scholar
• Addeo R, De RC, Faiola V, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113:2524-31
   PubMed Web of Science ®Google Scholar
• Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9
   PubMed Web of Science ®Google Scholar
• Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2010;22:625-30
   Google Scholar
• Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases–the UK experience. Br J Cancer 2010;102:995-1002
   PubMed Web of Science ®Google Scholar
• World Health Organization. International Classification of Diseases - 10th Revision (ICD-10). WHO, 2007. http://www.who.int/classifications/icd/en/. Accessed February 15, 2010
   Google Scholar
• Koninki K, Tanner M, Auvinen A, et al. HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res 2009;11:R37
   PubMedGoogle Scholar
• Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
   PubMed Web of Science ®Google Scholar
• Horiguchi H, Yasunaga H, Hashimoto H, et al. Incidence of severe adverse events requiring hospital care after trastuzumab infusion for metastatic breast cancer: a nationwide survey using an administrative claim database. Breast J 2011;17:683-5
   Google Scholar
• Benjamin L, Cotte FE, Philippe C, et al. Physicians’ preferences for prescribing oral and intravenous anticancer drugs: a discrete choice experiment. Eur J Cancer 2011;October 25 [Epub ahead of print]
   Google Scholar
• Harputluoglu H, Dizdar O, Aksoy S, et al. Characteristics of breast cancer patients with central nervous system metastases: a single-center experience. J Natl Med Assoc 2008;100:521-6
   PubMed Web of Science ®Google Scholar
• Pez E, Gauchez AS, Payan R, et al. Brain metastases exploration in metastatic breast cancer treated with Herceptin®: a place for biological tools? Immuno-Anal Biol Spéc 2007;22:151-5
   Google Scholar
• Remy V, Mathevet P, Vainchtock A. Vulvar and vaginal cancers and dysplasia in France–an analysis of the hospital medical information system (PMSI) database. Eur J Obstet Gynecol Reprod Biol 2009;147:210-4
   Google Scholar
• Allen JM. Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care 2010;16:697-704
   PubMed Web of Science ®Google Scholar
• Dahlberg L, Lundkvist J, Lindman H. Health care costs for treatment of disseminated breast cancer. Eur J Cancer 2009;45:1987-91
   PubMed Web of Science ®Google Scholar
• Galy G, Labidi-Galy SI, Perol D, et al. Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006. Breast Cancer Res Treat 2010;128:187-95
   Google Scholar
• Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004;91:77-83
   Google Scholar
• Pelletier EM, Shim B, Goodman S, et al. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 2008;108:297-305
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Zaher C, Wade S, et al. Outpatient cancer drug costs: changes, drivers, and the future. Cancer 2002;94:1142-50
   PubMed Web of Science ®Google Scholar